New CME/CE/ACPE-certified Activity

MedTalk1 - Management of the Patient with Chronic Hepatitis C
Chronic hepatitis C is a serious viral disease associated with significant and preventable morbidity and mortality, affecting an estimated 3.5 to 5 million patients. This activity will focus on improving the outcomes among patients with chronic hepatitis C by increasing awareness of its epidemiology, diagnosis and management, guidelines for antiviral treatment, and the management of patients who have achieved SVR.


Launch Program



MedTalk2 - Management of the Patient with Hepatitis B
Chronic hepatitis B and C are the major risk factors for hepatocellular carcinoma (HCC) in the US, and physicians often fail to follow HCC screening recommendations. Studies show that less than 20% of patients at high risk for HCC ever undergo surveillance. Prognosis is typically poor when HCC is diagnosed late; survival rates of patients with advanced untreated disease are reported to be less than 6 months. However, when identified and treated in earlier stages, HCC 5-year survival rates may approach 80 percent, underscoring the need for surveillance and screening of those at risk. The advent of direct-acting antiviral (DAA) therapies leading to reduced viral load has been a major breakthrough in reducing the risk of HCC; nonetheless, surveillance for cancer must be continued due to residual HCC risk.


Launch Program



MedTalk3 - Reducing the Risk of HCC in Patients with Hepatitis B and Hepatitis C Infection
Chronic hepatitis B and chronic hepatitis C are the major risk factors for hepatocellular carcinoma (HCC) in the US, and physicians often fail to follow HCC screening recommendations. Studies show that less than 20 percent of patients at high risk for HCC ever undergo surveillance. Prognosis is typically poor when HCC is diagnosed late; survival rates of patients with advanced untreated disease are reported to be less than 6 months. However, when identified and treated in earlier stages, HCC 5-year survival rates may approach 80 percent, underscoring the need for surveillance and screening of those at risk. The advent of direct-acting antiviral (DAA) therapies leading to reduced viral load has been a major breakthrough in reducing the risk of HCC; nonetheless, surveillance for cancer must be continued due to residual HCC risk.


Launch Program



The primary goal of this program is to improve outcomes of individuals with CHB by increasing the awareness and knowledge of the prevalence and impact of medical comorbidities on treatment selection on long-term patient management among health care providers practicing in Asian American communities.


Launch Program



New AHF Online Hepatitis B CME Activity Now Available!

The laboratory reports your patient's HBV serology results. Do you know how to interpret them?

Who? What? and What Next? Patient Identification and Evaluation in Chronic HBV addresses who should be screened, test result interpretation, serologic marker of HBV infection, monitoring vs. treatment and more.

Please visit:
Click here for more information and to register.

 

Archived Content
(
These programs are for reference only - there is no CME/CE credit available)

Overcoming Barriers To Hepatitis B Testing and Treatment in Asian Communities.
This is a case-based audio slide presentation that provides the most current information on Hepatitis B screening, diagnosis, and treatment from the USPSTF, AASLD, and recent clinical studies to improve patient outcomes in Asian American communities.


Strategies & Solutions for Hepatitis B Screening, Testing, Linkage to Care, & Treatment

DOWNLOAD the AHF 2012 Dinner Meeting Series Slide Deck - New Insights into Hepatitis B Diagnosis and Treatment *For reference only - there is no CME / CE credit available

DOWNLOAD the new B Aware for Care Monograph

 





 


To donate to the AHF, Please click here
to be redirected to our PayPal Account.

 

© Copyright 2018 Asian Health Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the AHF terms of use and privacy statement.

Download HCCLinks.org HepBlink.org